ClinicalTrials.gg
RecruitingNCT05026749Updated Feb 9, 2026

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

A Phase 3 interventional study of AZM Group and Control Group in Respiratory Syncytial Virus Infections, sponsored by University of Alabama at Birmingham. Recruiting at 15 sites in United States. Open to participants aged 3 Days to 2 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by University of Alabama at Birmingham · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
370
Allocation
Randomized
Ages
3 Days to 2 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies in Respiratory Syncytial Virus Infections with a site in United States — 10 open to participants now, 14 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · United States.

Planned enrollment
38th of 122
370 · median 88
Started
2022
with 10 others
Phase 3
26 of 145
2 open now
Primary completion
2027-07
later than 7 of 13 live
Registered
94th of 145
by date

Among the 145 studies in Respiratory Syncytial Virus Infections with a site in United States, this one is the 38th largest by planned enrollment of the 122 interventional ones that give a count, is one of 11 that started in 2022, is one of 26 in phase 3, reaches primary completion later than 7 of the 13 other live ones, and was the 94th registered.

Respiratory Syncytial Virus Infections

307 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 50 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

10 of the 145 studies in Respiratory Syncytial Virus Infections with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 3 Days to 2 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Respiratory Syncytial Virus Infections with a site in United States, or all of them as a file.
02

Study summary

The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.

Read the detailed description

The proposed study will be a randomized, double-blinded, placebo-controlled Phase III trial to examine the efficacy of AZM therapy relative to placebo in reducing RSV-related morbidity. Patients will be recruited during acute hospitalization and admission to the ICU at 10 pediatric hospitals. The target population selected is pediatric patients with severe RSV lung disease as defined by need for ICU management and intensive respiratory support.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • RSV
  • AZM
  • ICU
  • Respiratory Support
  • Children
04

Who can participate

Ages eligible
3 Days to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admission to the pediatric ICU with a confirmed diagnosis of RSV infection. RSV infection is based on a positive nasal swab for RSV fluorescent antibody or via multiplex assay or culture;
  • Requiring intensive respiratory support defined as either mechanical ventilation or NIV (BiPAP or CPAP) or HFNC (at >1 L/kg/min of flow
  • Enrollment into the study within 48 hours of ICU admission and placement on intensive respiratory support;
  • Onset of RSV-related symptoms must be less than 5 days
  • Age: Neonates-2 years. For those less than 1 week of age, they must have been discharged home from the hospital after their birth.

Exclusion criteria

Exclusion criteria:

  • AZM use within 7 days of ICU admission;
  • to AZM use including known to AZM, erythromycin, any macrolide, or ketolide drug, patients with significant hepatic impairment (direct >1.5 mg/dL or ≥ 10 times the );
  • Patients with known cardiac disease, cardiac arrhythmia or with corrected for heart rate (QTc) ≥ 450 milisecond (ms);
  • Intensive respiratory support greater than 48 hours prior to ICU admission;
  • Chronic ventilation or supplemental oxygen need at home;
  • conditions such as those post heart or hematopoietic stem cell transplant or receiving chemotherapy and chronic ;
  • History of pyloric stenosis;
  • AZM is deemed necessary for clinical treatment (for instance, if patient has pertussis).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
370 participants (estimated)

Study arms

  • Placebo comparator
    Control Group

    Other: Control Group

  • Active comparator
    AZM 20mg/kg Treatment Group

    Drug: AZM Group

Interventions

  • DrugAZM Group

    AZM at 20 mg/kg will be given intravenous daily for 3 days once patients are consented and enrolled into the study.

  • OtherControl Group

    Saline will be given intravenous daily for 3 days once patients are consented and enrolled into the study.

06

What researchers measure

Primary outcomes

  1. Length of Hospitalization

    Duration of hospitalization in days for enrolled subjects

    Time frame: At discharge (Approximately 2 weeks)

Secondary outcomes

  1. Duration of oxygenation

    Duration of oxygenation in days for enrolled subject

    Time frame: At discharge (Approximately 1 week)

  2. Length of ICU stay

    Duration of ICU stay in days for enrolled subjects

    Time frame: At ICU discharge (Approximately 1 week)

07

Study locations

15 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — To be determined.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jul 2027, 64 months after the start.

Of 32 phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 64 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2021
First posted
Aug 30, 2021
StartActual
Feb 27, 2022
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 31, 2028
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05026749
Responsible party
Michele Kong, MD (PI, University of Alabama at Birmingham) — Principal investigator
First posted
Aug 30, 2021
Start date
Feb 27, 2022
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Feb 9, 2026

Study contacts

Michele Kong, MD
Contact
mkong@uabmc.edu
205-638-9387
Michele Kong, MD
principal investigator · The University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion